Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond
By Xcenda
Brian Biehn, senior director of biosimilar commercialization, and Corey Ford, vice president of reimbursement and patient access, and policy insights at Cencora (formerly AmerisourceBergen) join the Not So Different podcast from The Center for Biosimilars. They explore how 2023 sets up a new chapter for the biosimilar industry.
As 2023 bids farewell, we reflect on the remarkable advancements witnessed in the biosimilar industry over the past year. From the highly anticipated market introduction of adalimumab biosimilars in the US to significant regulatory approvals for neurology biosimilars, and the implementation of key policy initiatives worldwide, it has been a transformative period. All eyes are now on 2024 as the biosimilar industry gears up for another pivotal year, with upcoming approvals for denosumab, aflibercept, and on-body pegfilgrastim biosimilars in the United States. However, there are crucial questions left unanswered.
- How will the implementation of the Inflation Reduction Act (IRA) impact Medicare price negotiations?
- What role will interchangeability designations play in adoption rates?
- And most importantly, will payers and pharmacy benefit managers be ready to embrace newer biosimilars and include them as preferred products?
